67-第67章 多发性肌炎和皮肌炎

可乐加水

随着免疫抑制治疗的出现，特发性炎性肌病的预后不断改善。皮质激素出现前成人特发性炎性肌病的5年生存率为60%,1947一1968年为 68%，近几年为 80 。用通信方式对1986一1998年的59例特发性炎性肌病病人进行了随访，一年生存率为90%,2-5年生存率为80%。前5年共死亡12例，其中死于肺内感染5例，肺纤维化4例，肿瘤3例。发病前3年病情较重，激素用量大，激素减量或停用时病情易复发;发病5年后病情趋于稳定，有三分之一的病人脱离激素，病情仍保持稳定。我们的病人多数较重，病例也较少，因此，这些统计数字与实际情况可能会有差异，它只是在一定程度上也反映了一种趋向。除使用免疫抑制剂外，早诊断早治疗，以及有效控制并发症也有助于预后的改善。
1 n6 u8 Z+ z- l8 n/ q' H8 c; u0 R                                                                                                                (吴东海)
      参考文献：
. ]1 B/ K4 p4 P7 B5 k  g
       马丽，王丽英，侯广庆，等 皮肌炎多发性肌炎59例随访.中华风湿病学杂志，5:59一61   
5 J& b/ ]/ Y2 f; ?6 ?7 b
( c7 u2 j% ^! ^& |% @% I9 e' a      Askanas V, Engel W N. Sporadic inclusion-body myositisand hereditary inclusion body myopathies: current concepts of di-agnosis and pathogenesis. Curr Opin Rheumatol, 1998.10:530  
# a; D) V2 ?: d- v  q4 e" u
      Ausem M G E M, Lochman P, van Diggelen O P, et al. Adiagnostic test for adult-onset glycogen storage disease type 11.Neurology, 1999.52:851  

2 J, z0 J7 }0 o      Behrens L, Bender A, Johnson M A, et al. Cytotoxic mech-anisms in inflammatory myopathied co-expression of Fas and pro-tective Bcl-2 in muscle fibers and inflammatory cells. Brain,1997. 120:929
/ Z  c2 S3 Q& n5 m# Y8 K5 {% L& c
% Z! w5 H) V" e      Dalakas M C,Dambrosia J M. A controlled trial of high-doseintravenous immuneglobulin infusions as treatment for dermato-myositis. N Engl J Med, 1993. 329:1993一2000
) |4 V- W$ A$ B0 z( \( C# C& h
      Fafalak R G, Peterson M G, Kagen L J. The strength inpolymyositis and dermatomyositis: best outcome in patients treat-ed early. J Rheumatol, 1994.21:643一648

) w( N; E7 s9 g' o* J4 d      Fyher I-M, Moslemi A-R, Mosavia A, et al. Oligoexpres-sion in muscle infiltrating T cells in inclusion body myositis. JNeuroimmunol 1997.79:185

, r, Q. r5 C$ `& [      Garlepp M J, Mastaglia F L. Inclusion body myositis. JNeurol Neurosurg Psychiatry, 1996. 60:251一258
$ C$ B; Y% ^+ E: t6 y' w: c      Garton M J, Isenberg D A. Clinical features of lupus myosi-tis versus idiopathic myositis: A review of 30 cases.  Br JRheumatol, 1997.36:1067
$ p4 l3 ~5 \3 ]1 g7 h! y+ y; e! P( t
      Goebels N, Michaelis D, Engelhardt M, et al. Differentialexpression of perforin in muscle-infiltrating T cells in polymyositisand dermatomyositis. J Clin Invest, 1996.97:2905  
, i  M5 U% d( y* p
      Gonzalez-Lopez L, Gamez-Nava JI, Sanchez L, et al. Car-diac manifestations in dermato-polymyositis. Clin Exp Rheumatol1996. 14:373

      Mantegazza R, Bernasconi P, Confalonieri P, et al. Inflam-matory myopathies and systemic disorders: a review of im-munopathogenetic mechanisms and clinical features. J Neurol,1997. 244:277

      Marie 1, Horton P-Y, Hachulla E, et al. Pulmonary in-volvement in polymyositis and in dermatomyositis. J Rheumatol,1998. 25:1336

3 \0 x! B) j0 _2 P$ D2 G2 g2 X      Naparstek Y, Plotz P H. The role of autoantibodies in au-toimmune disease. Ann Rev Immunol, 1993.11:79一104   
, L- }1 M- E; K7 I4 m2 s$ H
2 o) v8 J; V0 S9 m, g      Pascuzzi R M. Drugs and toxins associated with myopathies.Curr Opin Rheumatol, 1998.10:511   

      Pickering M C, Walport M J. Eosinophilic myopathic syn-dromes. Curr Opin Rheumatol,1998. 10:504

# l; B. m. \& m& d- `5 c" F. c      Plotz P H, Rider L G，Targoff I N, et al. NIH conference.Myositis:  immunologic contributions to understanding cause,pathogenesis and therapy. Ann Intern Med, 1995-122: 715一724

      Robert L. Wortmann. Inflammatory Diseases of Muscle andOther Myopathies. Kelley’s Textbook of Rheumatology, 6thEd，W. B. Saunders Company. 2001  

      Sieb J P, Ries F, Traber, et al. Recurrent focal myositis.Muscle Nerve, 1997. 20:1205

      Targoff I N, Miller F W, Medsger T A Jr, et al. Classifica-tion criteria for the idiopathic inflammatory myopathies. CurrOpin Rheumatol, 1997.9:527  

6 J2 y* v5 v: q. s+ r! ?  g      Villalba L, Hicks J E, Adams E M, et al. Treatment of re-fractory myositis. Arthritis Rheum 1998. 41:392  
/ K2 g1 V( H3 W* W$ T7 e) t
) R) L* S' V! b      Whitemore S E, Watson R, Rosenshein N B, et al. Der-matomyositis sine myositis:  Association with malignancy.  JRheumatol, 1996.23:1010

8 m" J9 x5 A9 g" t: G+ B: v      Zieglschmid M E, Pandya A G, Cohen S B, et al. Treat-ment of dermatomyositis with methotrexate. J Am Acad Derma-tol, 1995.32:754一757